Skip to main content
Browse Subject Areas

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

Association of herpesviruses and stroke: Systematic review and meta-analysis

  • Harriet J. Forbes ,

    Roles Conceptualization, Data curation, Formal analysis, Methodology, Writing – original draft, Writing – review & editing

    Affiliation Faculty of Epidemiology & Population Health, LSHTM, London, United Kingdom

  • Elizabeth Williamson,

    Roles Conceptualization, Methodology, Writing – review & editing

    Affiliation Faculty of Epidemiology & Population Health, LSHTM, London, United Kingdom

  • Laura Benjamin,

    Roles Conceptualization, Methodology, Writing – review & editing

    Affiliations Institute of Infection and Global Health, University of Liverpool, Liverpool, United Kingdom, Stroke Research Centre, Department of Brain Repair and Rehabilitation, UCL Institute of Neurology, UCL, London, United Kingdom

  • Judith Breuer,

    Roles Conceptualization, Methodology, Writing – review & editing

    Affiliation UCL Division of Infection & Immunity, UCL, London, United Kingdom

  • Martin M. Brown,

    Roles Conceptualization, Methodology, Writing – review & editing

    Affiliation Stroke Research Centre, Department of Brain Repair and Rehabilitation, UCL Institute of Neurology, UCL, London, United Kingdom

  • Sinéad M. Langan,

    Roles Conceptualization, Methodology, Writing – review & editing

    Affiliation Faculty of Epidemiology & Population Health, LSHTM, London, United Kingdom

  • Caroline Minassian,

    Roles Conceptualization, Methodology, Writing – review & editing

    Affiliation Faculty of Epidemiology & Population Health, LSHTM, London, United Kingdom

  • Liam Smeeth,

    Roles Conceptualization, Methodology, Writing – review & editing

    Affiliation Faculty of Epidemiology & Population Health, LSHTM, London, United Kingdom

  • Sara L. Thomas,

    Roles Conceptualization, Methodology, Writing – review & editing

    Affiliation Faculty of Epidemiology & Population Health, LSHTM, London, United Kingdom

  • Charlotte Warren-Gash

    Roles Conceptualization, Methodology, Supervision, Writing – review & editing

    Affiliation Faculty of Epidemiology & Population Health, LSHTM, London, United Kingdom



Herpesviruses induce a range of inflammatory effects potentially contributing to an increased risk of stroke.


To investigate whether patients with infection, or reactivation of, human herpesviruses are at increased stroke risk, compared to those without human herpesviruses.

Data sources

Six medical databases and grey literature sources from inception to January 2017.

Study eligibility criteria

Studies where the exposure was any human herpesvirus and the outcome was stroke. We included randomised controlled trials, cohort, case-control, case-crossover and self-controlled case series designs.


Meta-analyses when sufficiently homogeneous studies were available. Quality of evidence across studies was assessed.


We identified 5012 publications; 41 met the eligibility criteria. Across cohort and self-controlled case series studies, there was moderate quality evidence that varicella infection in children was associated with a short-term increased stroke risk. Zoster was associated with a 1.5-fold increased stroke risk four weeks following onset (summary estimate: 1.55, 95%CI 1.46–1.65), which resolved after one year. Subgroup analyses suggested post-zoster stroke risk was greater among ophthalmic zoster patients, younger individuals and those not prescribed antivirals. Recent infection/reactivation of cytomegalovirus and herpes simplex viruses, but not past infection, was associated with increased stroke risk; however the evidence across studies was mainly derived from small, very low quality case-control studies.


Our review shows an increased stroke risk following zoster and suggests that recent infection or reactivation of other herpesviruses increases stroke risk, although better evidence is needed. Herpesviruses are common and potentially preventable; these findings may have implications for reducing stroke burden.


Globally, stroke is the second most frequent cause of death.[1] There is a growing literature indicating that infections, particularly acute respiratory and urinary infections, may play a role in triggering vascular events.[2] Herpesviruses are a family of common viruses persisting latently after primary infection and reactivating periodically. The viruses induce a range of inflammatory effects,[2] potentially contributing to thrombogenesis, atherosclerosis, vasculopathy and platelet activation and thus an increased risk of stroke.

Six previous reviews support an association between herpes zoster (caused by the reactivation of varicella zoster virus (VZV)) and stroke.[38] One reported a risk ratio of 1.36 (95%CI 1.10–1.67) for the association between zoster and stroke pooled across six cohort studies,[4] whilst the other reviews found around 2-fold increased risk shortly after zoster, which decreased over the following year.[3, 57] Cytomegalovirus (CMV) is also hypothesised to modulate stroke risk, especially among immunocompromised populations[9] and a recent systematic review concluded that cytomegalovirus infection is associated with an increased risk of cardiovascular disease.[10]

Although these reviews have made a significant contribution, there are certain limitations, such as; exclusion of self-controlled case series (SCCS),[4] exclusion of studies among children,[38] limited subgroup analyses (only one study assessed whether antiviral therapy modified stroke risk)[7] and restricted scope by looking exclusively at clinically apparent zoster and stroke risk. Studies assessing any of the eight herpesviruses known to infect humans and utilising laboratory tests and serological analysis, as well as clinical diagnoses, could also help elucidate the role of latent, sub-clinical or clinical infection and stroke risk.

The primary objective of the systematic review was therefore to investigate whether patients with infection, or reactivation of, human herpesviruses are at increased risk of stroke,


The protocol was published[11] according to the Preferred Reporting Items for Systematic Reviews and Meta Analyses Protocols guidelines (PROSPERO registration number:CRD42017054502).

Study designs and characteristics

Eligible study designs included cohort, case-control, case-cohort, case-crossover and SCCS designs. Randomised controlled trials investigating prevention or treatment of herpesvirus infection or reactivation (using vaccines or antiviral agents) were also eligible. We excluded cross-sectional studies, ecological studies, case-series, case-reports and reviews. Studies were required to report an effect estimate or the data that allow its calculation. We placed no restrictions on time period, publication status, language, geographical setting or healthcare setting.


Eligible studies included human participants. No restrictions were placed participants’ on age or immunosuppression status.


The exposures of interest were infection with, or reactivation of, the eight human herpesviruses: specifically, herpes simplex virus types 1 and 2 (HSV-1 and HSV-2), VZV, Epstein-Barr virus (EBV), CMV, herpesvirus 6, 7, and 8. The exposure definition could be self-reported or a confirmed diagnosis, either through clinical or laboratory criteria. Vaccination against herpesviruses (e.g. Zostavax vaccine) and treatment for herpesviruses (e.g. antivirals) were also considered as effect modifiers, to investigate whether preventing or treating human herpesviruses attenuated stroke risk.


Eligible studies were required to include a comparison group of people (or person time for SCCSs or case-crossover) without the herpesvirus exposure of interest.


Studies were included if stroke (first ever or subsequent) was an outcome, clinically diagnosed or self-reported. Those studies meeting the inclusion criteria were additionally assessed for secondary outcomes: TIA[12] and subtypes of stroke (ischaemic versus haemorrhagic).

Information sources

We searched for eligible articles in six databases, originally from dates of inception to January 2017, and then again in July 2018 limited to the years 2017 and 2018. The databases included Cochrane Central Register of Controlled Trials, Embase, Global Health, Medline, Scopus and Web of Science. We additionally searched the clinical trials registers ( and grey literature sources, including the New York Academy of Medicine Grey Literature Report ( and the Electronic Theses Online Service through the British Library (

Search strategy

We searched medical subject heading terms and free text (in the title and abstract) for the concepts ‘human herpesviruses’ and ‘stroke’ (combined with the Boolean logic operator AND). Search terms were developed for the database Medline, reviewed by all collaborators and subsequently transcribed into search terms for the remaining databases (supplementary information S1 Appendix for search terms). Reference lists of eligible articles and relevant reviews were scanned for additional papers.

Study selection

Eligibility assessment was performed independently in a blinded standardized manner by two reviewers (CWG and HF); all retrieved titles and abstracts were screened.

Data collection process

Data were extracted using a pre-defined standardised template. Extraction criteria were based on the PICOS[13] (Population, Intervention, Comparator, Outcomes and Study design) framework. As this is an aetiological study, “exposure” replaced “intervention” and “study characteristics” broadened to “study design” (S3 Appendix for all items extracted). We also recorded: the most fully adjusted effect estimates (odds ratios, hazard ratios, incidence rate ratios, risk ratios) for the association between the exposure and stroke; confounders adjusted for; and results of additional analyses relevant to our non-primary objectives. If there were no events in one arm of the study, a continuity correction was applied (adding 0.5 to each cell[13]).

Risk of bias in individual studies

Two authors independently assessed risk of bias in three studies and HF completed the remaining studies. In keeping with the Cochrane Collaborations approach,[1416] a pre-specified set of domains were considered, including bias due to: 1) confounding; 2) selection of participants; 3) differential and non-differential misclassification of exposure and outcome; 4) missing data; and 5) reverse causation. For each domain, a-priori criteria were set-out to assign ‘high’, ‘low’, ‘moderate’, or ‘unclear’ risk. A summary risk of bias table was produced; when a domain had more than one item the highest risk of bias judgment was used (unless the only item at high-risk was non-differential misclassification, which would bias results toward the null).

Synthesis of results

We synthesised the results into a narrative, grouping studies by herpesvirus exposure and study design; subgroup analyses were also described. We classified exposures as past infection or recent infection/reactivation. IgM and IgA antibodies, and DNA, are present in the blood for a limited period following herpesviruses exposure, therefore their presence suggests recent infection or reactivation (though IgM has poor sensitivity for detecting acute infections and poor specificity in immunosuppressed).[17] Conversely, IgG antibodies, although also raised during an acute infection or reactivation, remain during latent infection, therefore were classified as a past infection.[17] We also presented results from studies of high versus low IgG titre, as high IgG titre may reflect recent reactivation.

When at least two studies assessed the same herpesvirus as a stroke risk factor, meta-analysis was considered. For pooling, we required studies to have identical study designs, the same measurement for the herpesvirus (e.g. IgG seropositivity) and identify the outcome within a similar time-frame. We pooled effect sizes (referred to as “summary estimates”) irrespective of the type of effect estimate, due to stroke being rare. Random effects meta-analysis was used throughout, to ensure a consistent approach to all analyses was employed; the I2 statistic indicated moderate heterogeneity (I2>25%) for many subgroups. We investigated sources of heterogeneity (where there were at least three studies in the meta-analysis) by removing studies at high-risk of bias.

Quality of the evidence

The Grading of Recommendations, Assessment, Development and Evaluation (GRADE)[18] approach was used to summarise the quality of cumulative evidence for each herpesvirus on stroke. Evidence was categorised as ‘high’, ‘moderate’, ‘low’ or ‘very low’ quality, with observational studies starting as ‘low’; five reasons to rate down and three reasons to rate up the quality of evidence, were then considered.[19] Full criteria for grading is in S4 Appendix. We assessed publication bias when there were at least 10 studies by creating a funnel plot: effect estimates for the exposure on stroke risk were plotted against standard errors of the log odds, and symmetry was assessed visually and using Begg’s test for small-study effects.[20]


As this is a systematic review, ethical approval is not required.


In our initial search 5012 titles and abstracts were screened and 41 observational studies were selected for review (Fig 1). Our updated search retrieved 607 studies, of which seven were selected for review, making a total of 48 studies for the final review.

Study methods and results are summarised in Tables 1 and 2 respectively, risk of bias for individual studies in Table 3 (S5 Appendix for detailed justification) and GRADE assessment in Table 4. Results and meta-analyses are displayed in Figs 24.

Fig 2. Effect of clinically diagnosed herpes zoster on stroke risk by study design and length of follow-up.

†Outcome was ischaemic stroke ‡Outcome was stroke/TIA μ: among patients 50–60 years of age. •Study population was immunosuppressed *Comparator group was person time 366-730days after HZ.

Fig 3. Effect of CMV (serological evidence of infection or clinical reactivation) on stroke risk.

†Outcome was ischaemic stroke ‡Outcome was stroke/TIA •Study population was immunosuppressed. ‼No age adjustment/matching for age.

Fig 4. Effect of EBV, HSV, VZV infection, clinically diagnosed varicella and VZV vaccination on stroke risk.

†Outcome was ischaemic stroke ‡Outcome was stroke/TIA ‼No age adjustment/matching for age.

Table 3. Risk of bias summary showing judgements about each risk of bias domain.

17 studies assessed the association between zoster and stroke (1 case-control study,[21] 13 cohort studies[2234] and 3 SCCS[3537]) (Table 1). Ten were based in the US or Europe and six in Asia and one in the Middle East; all studies used routinely collected medical records. Two studies involved an immunosuppressed population. 8/17 studies were considered at low-risk of bias in all domains.

Zoster was associated with a 1.5-fold increased stroke risk four weeks following onset (summary estimate: 1.55, 95%CI 1.46–1.65), with the risk decreasing to baseline after around one year (Fig 2). Removing three studies at high-risk of bias eliminated statistical heterogeneity in cohort studies with “Over 1 year follow-up” (I2<0.01%, see S1 Table). There were no SCCS at high-risk of bias. There was moderate quality evidence of an increased risk of stroke following zoster, with evidence upgraded due to some strong associations and a clear dose-response gradient over time.

Two studies reported an increased risk of TIA following zoster. The first showed over 50% increased risk (IRR1.56, 95%CI:1.13–2.15) over a maximum of 10 years follow-up[34] and the second around 15% increased risk (HR1.15, 95%CI:1.09–1.21) during a median follow-up of 6.3 years.[22] Only a single SCCS study assessed the effect of zoster vaccination on stroke risk, using Medicare claims data; this study found no evidence that zoster vaccination attenuated stroke risk, however only 3% of study participants were vaccinated which limited the study’s ability to detect an effect.[35]

Results can be found in S1, S2, S3, S4 and S5 Figs. Ophthalmic zoster was associated with increased risk of stroke, of a larger magnitude than zoster at any site. The pooled estimate for stroke up to 4 weeks following ophthalmic zoster in SCCSs was 1.77 (95%CI:1.53–2.05), compared to 1.55 (95%CI:1.46–1.65) following any zoster (S1 Fig). Another study found the elevated risk of stroke among rheumatoid arthritis patients experiencing zoster was greatest in those patients with a neurological complication.[33] Antiviral agents appeared to attenuate stroke risk in two out of three studies, though the confidence intervals for effect estimates for zoster patients given and not given antivirals overlapped (S2 Fig). In one SCCS study, in the first four weeks following zoster there appeared to be no evidence of an increased risk of stroke among those given antivirals (IRR1.23, 95%CI:0.89–1.70), whilst for those not given antivirals there was an association (IRR2.14, 95%CI:1.62–2.83). A larger effect of zoster on stroke risk was seen in people aged below 40 years (S3 Fig); there was no difference of zoster on stroke risk by gender (S4 Fig); and little difference in stroke risk by stroke type (ischaemic versus haemorrhagic), except in one cohort study from Taiwan[24] where the magnitude of association was greater for haemorrhagic stroke (S5 Fig).

CMV infection, defined largely using laboratory criteria, was investigated in 22 studies[9, 30, 3857] using data from a variety of settings including electronic healthcare records, survey data and trial data (Table 1).

Among studies assessing CMV infection (past or recent), 19/22 studies had a least one domain at high-risk of bias, including: confounding (ten studies had no age-adjustment) and reverse causation (10 studies recorded CMV following stroke).

14 studies investigated past CMV infection and stroke risk (Fig 3); IgG seropositivity and/or high titre IgG antibodies were investigated. IgG seropositivity was not associated with stroke when combining six case-control studies (summary estimate:1.40, 95%CI:0.67–2.96; I2 = 78.8%) nor in cohort studies (summary estimate:1.01,95%CI:0.73–1.39, I2<0.001%). While having a high IgG titre compared to a low titre was associated with stroke when combining two case-control studies (summary estimate:2.61,95%CI:1.26–5.43, I2 = 33.4%) it was not associated with stroke when pooling three cohort studies (summary estimate:0.80,95%CI:0.62–1.05, I2<0.001%).

Recent CMV infection or reactivation was investigated in 11 case-control studies (Fig 3), using a variety of exposure definitions. In a meta-analysis of two studies, IgM seropositivity was associated with increased stroke risk (summary estimate:5.53,95%CI:2.83–10.81, I2<0.001%). When pooling three studies, CMV DNA was also associated with increased stroke risk (summary estimate:2.34,95%CI:0.95–5.74, I2 = 81.4%). In two of three studies among immunosuppressed patients, clinical CMV reactivation was associated with around 3-fold increased risk of stroke.

There was very low-quality evidence suggesting there is no association between past infection with CMV and stroke and an increased risk of stroke following recent infection/reactivation with CMV.

CMV was the only outcome for which sufficient studies were available to assess publication bias; there was no evidence of publication bias (see S6 Fig).

One case-control study assessed the association between HHV-6 and stroke; no association was found.[58] Four case-control studies examined the association between EBV and stroke (Table 1);[50, 51, 53, 55] three were hospital-based among older adults and one a multi-country study among children (under 18 years). All studies were small (N<500) and at high-risk of bias.

There was no evidence that past infection (IgG seropositivity) was associated with stroke risk, when combining data from three studies (summary estimate: 1.28, 95%CI:0.89–1.84; I2<0.001) (Fig 4). The study among children found no evidence that recent infection/reactivation of EBV (measured from IgM seropositivity) was associated with stroke risk (OR 1.44, 95% CI 0.12–16.75).

There was very low quality evidence of no association between past infection and an increased risk following recent infection/reactivation with EBV and stroke; the quality of evidence was downgraded due to high-risk of bias and imprecise estimates.

Associations between HSV-1 or HSV-2 and stroke risk were explored in seven studies[5054, 56, 57] (Table 1) using population survey data and an RCT, and data from a hospital setting. A high-risk of bias was identified in all seven studies. No clear patterns were observed, although there was some indication that recent HSV1 infection/reactivation (IgM seropositivity or IgA high titre) was associated with increased stroke risk.

Two case-control studies[51, 59] and one US-community based cohort study[57] assessed the effect of serologically-defined VZV infection on stroke risk (Table 1). Past infection (IgG seropositivity or high titre) was not associated with stroke risk in two studies (Fig 4); quality of evidence was graded very low due to a high-risk of bias. However, a multi-country case-control study among children (under 18 years) found recent infection/reactivation (IgM seropositivity) was associated with increased stroke risk; quality of evidence was graded as low, because although there was a high-risk of bias, the association was very strong.

Varicella and the risk of stroke among children was assessed in three studies from Canada and Europe;[6062] a high-risk of bias was identified in 2/3 studies. Different study designs and time periods during which stroke was recorded were used, therefore estimates were not pooled. However, each study found varicella was associated with a greater risk of stroke within a year from diagnosis. Because of the dose-response gradient over time and very strong associations observed, the evidence was classified as moderate quality.

The SCCS study also assessed the association among adults; an increased risk of stroke within 6-months of varicella was found (IR2.13, 95%CI:1.05–4.34). Although this association was strong, the confidence interval was wide, thus the evidence was graded low quality.

Five studies evaluated the short-term effect of VZV vaccination on stroke risk, by comparing vaccinated with unvaccinated people (or person time in the same individuals). One was a multi-country RCT[63] and the others used Canadian or US electronic healthcare records (Table 1);[6467] these studies were at very low-risk of bias. No decreased risk of stroke in those vaccinated against varicella or zoster was noted (Fig 4); evidence across studies was graded very low and low quality for varicella and zoster vaccination, respectively.

One small (N = 111) case-control study among older hospitalised patients found no association between HHV-6 IgG seropositivity and stroke (Table 1), in unadjusted analysis (OR 0.90, 95%CI:0.41–1.98).[53] No studies assessed herpesvirus-7 or 8.


Our review identified 48 studies assessing the association between infection with or reactivation of herpesviruses and risk of stroke. Consistent with previous reviews, there was moderate quality evidence that zoster was associated with a short-term increased risk of stroke, and that increased risk was greatest shortly after zoster (decreasing to baseline by around one year). Some evidence suggested the risk was greater among ophthalmic zoster patients, younger age groups and patients not prescribed antivirals. Moderate quality evidence suggests varicella was associated with increased stroke risk in children. Similar to findings for VZV, there may also be an increased stroke risk with recent CMV and HSV infection/reactivation, however the evidence was very low quality. Finally, there might be an increased stroke risk associated with recent CMV infection or reactivation based on studies carried out in immunosuppressed populations.

Two main pathophysiological mechanisms are proposed by which herpesviruses may increase stroke risk. Systemic infection with, or reactivation of, herpesviruses induces acute inflammation,[2] which may lead to endothelial dysfunction accompanied by disruption of atheromatous plaques and hypercoagulability.[68] This biological hypothesis is consistent with our finding that latent herpesvirus infection (that is, presence of viral DNA in host cells without producing infectious viral particles)[69] does not appear to increase stroke risk, as latent infection does not cause acute inflammation in host cells. Herpesviruses may also directly invade cerebral arteries, producing vasculopathy, leading to increased stroke risk;[70] this could explain why younger individuals, normally free from traditional vascular risk factors, were at higher risk of stroke following a recent infection/reactivation of VZV. VZV is the only virus with clear evidence of virus DNA in cerebral arteries; the stronger association between ophthalmic zoster and stroke also supports this hypothesis. CMV is associated with vasculopathy in immunocompromised patients, however the mechanism, and the risk in immunocompetent subjects are unclear.[71]

A larger effect of zoster on stroke risk was identified in people aged below 40 years. This has also been reported in a Korean-based cohort study. However, the absolute risk of stroke is low in younger ages, so a large relative effect may be small in absolute terms. This finding, together with the clinical efficacy of the currently available zoster vaccine becoming limited beyond 5–8 years,[72, 73] means vaccinating younger age groups may not be cost-effective.

This is the first study to systematically review the literature on all eight human herpesviruses as stroke risk factors and the results are broadly in-line with previous review assessing individual herpesviruses and cardiovascular disease (including stroke risk).[38, 10] Strengths included: following a pre-specified protocol; undertaking a comprehensive search; using articles published in any language; and carrying out a complete risk of bias assessment for each study and an assessment of the accumulated evidence using GRADE. Most studies ascertained stroke from pre-existing health care records (n = 33/41), potentially leading to similar stroke definitions across studies. A further strength of this review is that it not only included studies of clinically apparent herpesviruses reactivation, but subclinical reactivation. A further strength of this review is that it not only included studies of clinically apparent herpesviruses reactivation, but subclinical reactivation. It is possible that those with clinical manifestations of reactivated infection (e.g. zoster), or those who are immunosuppressed (as in some CMV studies), may have higher viral titres which plausibly could affect the risk of short term triggering of stroke.

However, limitations included having little data from low-income countries, which make up around 75% of stroke deaths worldwide;[74] whether different populations have different susceptibilities to stroke following herpesvirus infections is unclear. Some meta-analyses combined very few studies, limiting the strength of our pooled results. Overall, the quality of evidence for CMV, EBV and HSV was low or very low.

The studies of VZV, particularly zoster, were well-powered to assess the association between VZV and stroke and rarely suffered from a high-risk of bias; however, subgroup analyses were underpowered, limiting confidence in the findings. Studies of the other herpesviruses (CMV, EBV and HSV) had more limitations; many had small sample sizes, inadequate adjustment for confounders In addition to this, the majority of non-VZV studies relied on laboratory, rather than clinical, identification of possible recent infection or reactivation. The strength of the evidence for zoster and stroke risk lies in the studies all using clear clinical diagnoses of reactivated VZV, which was recorded prior to stroke. In contrast to VZV infection or reactivation which presents with clear clinical symptoms, other herpesviruses may reactivate without any clinical symptoms. Studies that measured markers of infection after stroke may suffer from reverse causality (all but one cases-control study–see Table 3) herpesvirus exposures were defined following stroke and stroke may trigger stress, leading to detection of herpesviruses reactivation after 24 hours (and blood samples were rarely taken immediately after stroke). This may explain why CMV IgG high (versus low) titre was associated with increased stroke risk in most case-control studies,[18] but not cohort studies (in which CMV antibodies were recorded prior to stroke). However, most case-control studies used hospital-based controls, so any stress associated with hospitalisation itself may affect cases and controls equally.

In terms of future research, high-powered cohort or SCCS studies assessing the association between recent infection with, and reactivation of, herpesviruses (aside from VZV), ideally collecting serology samples regularly during follow-up are needed. Furthermore, as zoster vaccination uptake increases, better-powered studies could confirm our findings that vaccination is not associated with a short-term increased stroke risk, and establish whether the vaccine reduces the long-term risk of stroke.

In terms of clinical practice, this review indicated that antivirals might attenuate stroke risk among zoster patients. As patients with more severe zoster are more likely to get antivirals, and also potentially more likely to have a stroke, this might have led to underestimation of their effect through confounding by indication. Antiviral drugs shorten zoster healing time and reduce pain severity[75] therefore these drugs may plausibly reduce stroke risk, by reducing inflammation. Antivirals for zoster are under-prescribed in UK primary care[76] and this review strengthens the argument for better adherence to prescribing guidelines.

Our review highlights that we have a good understanding of a short-term increased stroke risk following VZV infection and reactivation. It also suggests infection and reactivation of other herpesviruses may increase stroke risk, yet better evidence is required. Herpesviruses are common, therefore improved understanding of whether they increase the risk of stroke could provide additional strategies for stroke prevention.

Supporting information

S4 Appendix. Grade assessment of quality: Down/ up-grading reasons.


S5 Appendix. Reference list for selected studies.


S1 Fig. Effect of clinically diagnosed ophthalmic zoster on stroke risk, by study design and length of follow-up.


S2 Fig. Effect of zoster on stroke risk by length of follow-up and antiviral use during acute zoster.


S3 Fig. Effect of zoster on stroke risk by length of follow-up and age group.


S4 Fig. Effect of zoster on stroke risk by length of follow-up and gender.


S5 Fig. Effect of zoster on stroke risk by length of follow-up and type of stroke.


S6 Fig. Assessment of publication bias for CMV IgG seropositivity as a risk factor for stroke.


S1 Table. Exploring statistical heterogeneity identified in meta-analyses.



  1. 1. Feigin V.L., Forouzanfar M.H., Krishnamurthi R., et al. Global and regional burden of stroke during 1990–2010: findings from the Global Burden of Disease Study 2010. Lancet 2014. 383:245–54. pmid:24449944
  2. 2. Esenwa C.C. and Elkind M.S. Inflammatory risk factors, biomarkers and associated therapy in ischaemic stroke. Nature Reviews Neurology 2016. 12:594–604. pmid:27615422
  3. 3. Liu X.C., Guan Y.M., Hou L., et al. The Short- and Long-Term Risk of Stroke after Herpes Zoster: A Meta-Analysis. Plos One 2016. 11.
  4. 4. Yang S.Y., Li H.X., Yi X.H., et al. Risk of Stroke in Patients with Herpes Zoster: A Systematic Review and Meta-Analysis. J Stroke Cerebrovasc Dis 2016.
  5. 5. Lian Y., Zhu Y., Tang F., Yang B., and Duan R. Herpes zoster and the risk of ischemic and hemorrhagic stroke: A systematic review and meta-analysis. PLoS One 2017. 12:e0171182. pmid:28178287
  6. 6. Marra F., Ruckenstein J., and Richardson K. A meta-analysis of stroke risk following herpes zoster infection. BMC Infect Dis 2017. 17:198. pmid:28270112
  7. 7. Zhang Y., Luo G., Huang Y., Yu Q., Wang L., and Li K. Risk of Stroke/Transient Ischemic Attack or Myocardial Infarction with Herpes Zoster: A Systematic Review and Meta-Analysis. J Stroke Cerebrovasc Dis 2017. 26:1807–1816. pmid:28501259
  8. 8. Erskine N., Tran H., Levin L., et al. A systematic review and meta-analysis on herpes zoster and the risk of cardiac and cerebrovascular events. PLOS ONE 2017. 12:e0181565. pmid:28749981
  9. 9. Yen Y., Jen I., Chen M., et al. Association of cytomegalovirus end-organ disease with stroke in people living with HIV/AIDS: a nationwide population-based cohort study. PLoS ONE 2016. 11.
  10. 10. Wang H., Peng G., Bai J., et al. Cytomegalovirus Infection and Relative Risk of Cardiovascular Disease (Ischemic Heart Disease, Stroke, and Cardiovascular Death): A Meta-Analysis of Prospective Studies Up to 2016. J Am Heart Assoc 2017. 6.
  11. 11. Forbes H.J., Benjamin L., Breuer J., et al. The association between human herpesvirus infections and stroke: a systematic review protocol. BMJ Open 2017. 7:e016427. pmid:28554940
  12. 12. Sacco R.L., Kasner S.E., Broderick J.P., et al. An Updated Definition of Stroke for the 21st Century. A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association 2013. 44:2064–2089.
  13. 13. Higgins, J. and S. Green. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. 6.4.2 Structure of a search strategy. 2011; Available from:
  14. 14. Sterne J.A., Hernan M.A., Reeves B.C., et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 2016. 355:i4919. pmid:27733354
  15. 15. Higgins J.P., Altman D.G., Gotzsche P.C., et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011. 343:d5928. pmid:22008217
  16. 16. Sterne J.A., Hernán M.A., Reeves B.C., et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 2016. 355.
  17. 17. Fields B.N., Knipe D.M., and Howley P.M., Chapter 23—Alphaviruses in Fields virology. Sixth edition. ed. Virology. 2013: Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins.
  18. 18. Atkins D., Best D., Briss P.A., et al. Grading quality of evidence and strength of recommendations. British Medical Journal 2004. 328:1490–1494. pmid:15205295
  19. 19. Balshem H., Helfand M., Schunemann H.J., et al. GRADE guidelines: 3. Rating the quality of evidence. Journal of Clinical Epidemiology 2011. 64:401–406. pmid:21208779
  20. 20. Sterne J.A.C., Sutton A.J., Ioannidis J.P.A., et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. British Medical Journal 2011. 343.
  21. 21. Hosamirudsari H., Rashed P., Afsari F., Akbarpour S., and Bagherzadeh A. Correlation between herpes zoster and strokeA case-control study. Journal of Medical Virology 2018. 90:1370–1374. pmid:29704393
  22. 22. Breuer J., Pacou M., Gautier A., and Brown M.M. Herpes zoster as a risk factor for stroke and TIA: a retrospective cohort study in the UK. Neurology 2014. 83:e27–33. pmid:25002574
  23. 23. Calabrese L.H., Xie F., Yun H., et al. Herpes Zoster and the Risk of Stroke in Patients With Autoimmune Diseases. Arthritis Rheumatol 2017. 69:439–446. pmid:27588578
  24. 24. Kang J.H., Ho J.D., Chen Y.H., and Lin H.C. Increased Risk of Stroke After a Herpes Zoster Attack A Population-Based Follow-Up Study. Stroke 2009. 40:3443–3448. pmid:19815828
  25. 25. Kwon S.U., Yun S.C., Kim M.C., et al. Risk of stroke and transient ischaemic attack after herpes zoster. Clin Microbiol Infect 2016. 22:542–8. pmid:26992774
  26. 26. Lin H.C., Chien C.W., and Ho J.D. Herpes zoster ophthalmicus and the risk of stroke A population-based follow-up study. Neurology 2010. 74:792–797. pmid:20200348
  27. 27. Sreenivasan N., Basit S., Wohlfahrt J., et al. The Short- and Long-Term Risk of Stroke after Herpes Zoster—A Nationwide Population-Based Cohort Study. Plos One 2013. 8.
  28. 28. Sundstrom K., Weibull C.E., Soderberg-Lofdal K., Bergstrom T., Sparen P., and Arnheim-Dahlstrom L. Incidence of herpes zoster and associated events including stroke-a population-based cohort study. Bmc Infectious Diseases 2015. 15.
  29. 29. Tseng H.F., Smith N., and Jacobsen S. Incidence of Stroke Following Herpes Zoster among Population 50 Years and Older. Journal of Epidemiology and Community Health 2011. 65:A167–A167.
  30. 30. Yen Y.F., Chen M., Jen I., et al. Association of HIV and opportunistic infections with incident stroke: A nationwide population-based cohort study in Taiwan. Journal of Acquired Immune Deficiency Syndromes 2017. 74:117–125. pmid:27787346
  31. 31. Yawn B.P., Wollan P.C., Nagel M.A., and Gilden D. Risk of Stroke and Myocardial Infarction After Herpes Zoster in Older Adults in a US Community Population. Mayo Clin Proc 2016. 91:33–44. pmid:26704438
  32. 32. Kim M.C., Yun S.C., Lee H.B., et al. Herpes Zoster Increases the Risk of Stroke and Myocardial Infarction. Journal of the American College of Cardiology 2017. 70:295–296. pmid:28683973
  33. 33. Liao, T.L., C.H. Lin, H.H. Chen, Y.M. Chen, C.C. Lin, and D.Y. Chen. Significant associations of neurological complications of herpes zoster with stroke in rheumatoid arthritis patients. Journal of the American Heart Association 2017. 6 (7) (no pagination).
  34. 34. Patterson, B., D. Rausch, D. Irwin, M. Liang, S. Yan, and B. Yawn. Risk of transient ischemic attack and stroke in patients with herpes zoster: 2007–2014 US claims data analysis. Neurology. Conference: 70th Annual Meeting of the American Academy of Neurology, AAN 2018. 90.
  35. 35. Minassian C., Thomas S.L., Smeeth L., Douglas I., Brauer R., and Langan S.M. Acute Cardiovascular Events after Herpes Zoster: A Self-Controlled Case Series Analysis in Vaccinated and Unvaccinated Older Residents of the United States. Plos Medicine 2015. 12.
  36. 36. Schink T., Behr S., Thone K., Bricout H., and Garbe E. Risk of Stroke after Herpes Zoster—Evidence from a German Self-Controlled Case-Series Study. PLoS One 2016. 11:e0166554. pmid:27880853
  37. 37. Langan S.M., Minassian C., Smeeth L., and Thomas S.L. Risk of stroke following herpes zoster: a self-controlled case-series study. Clinical Infectious Diseases 2014. 58:1497–503. pmid:24700656
  38. 38. Coles K.A., Knuiman M.W., Plant A.J., Riley T.V., Smith D.W., and Divitini M.L. A prospective study of infection and cardiovascular diseases: the Busselton Health Study. Eur J Cardiovasc Prev Rehabil 2003. 10:278–82. pmid:14555883
  39. 39. Fagerberg B., Gnarpe J., Gnarpe H., Agewall S., and Wikstrand J. Chlamydia pneumoniae but not cytomegalovirus antibodies are associated with future risk of stroke and cardiovascular disease: a prospective study in middle-aged to elderly men with treated hypertension. Stroke 1999. 30:299–305. pmid:9933263
  40. 40. Gonzalez-Quijada S., Salazar-Thieroldt E., and Mora-Simon M.J. Persistent Q fever and ischaemic stroke in elderly patients. Clin Microbiol Infect 2015. 21:362–7. pmid:25630457
  41. 41. Huang Z.R., Yu L.P., Yang X.C., et al. Human cytomegalovirus linked to stroke in a Chinese population. CNS Neurosci Ther 2012. 18:457–60. pmid:22672297
  42. 42. Ķēniņa V., Auce P., Priede Z., et al., Cytomegalovirus chronic infection as a risk factor for stroke: a prospective study, in Proceedings of the Latvian Academy of Sciences. Section B. Natural, Exact, and Applied Sciences. 2010. p. 133.
  43. 43. Oliveras A., Roquer J., Puig J.M., et al. Stroke in renal transplant recipients: epidemiology, predictive risk factors and outcome. Clin Transplant 2003. 17:1–8. pmid:12588314
  44. 44. Shen X., Zhang W., Zhang S., and Cui M. The detection and clinical significance of serum HCMV IgM in patients with atherosclerosis and cerebral infarction. Journal of China Medical University 2011. 40:346–348.
  45. 45. Smieja M., Gnarpe J., Lonn E., et al. Multiple infections and subsequent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) Study. Circulation 2003. 107:251–7. pmid:12538424
  46. 46. Tarnacka B., Gromadzka G., and Czlonkowska A. Increased circulating immune complexes in acute stroke: the triggering role of Chlamydia pneumoniae and cytomegalovirus. Stroke 2002. 33:936–40. pmid:11935040
  47. 47. Yi L., Wang D.X., and Feng Z.J. Detection of human cytomegalovirus in atherosclerotic carotid arteries in humans. Journal of the Formosan Medical Association 2008. 107:774–81. pmid:18926944
  48. 48. Zheng L., Sun Z., Zhang X., et al. Human cytomegalovirus increases the risk of future hemorrhagic but not ischemic stroke—A nested case-control study. Circulation Journal 2016. 80:2235–2239. pmid:27499027
  49. 49. Ziemann M., Heringlake M., Lenor P., et al. Cytomegalovirus Serostatus as Predictor for Adverse Events After Cardiac Surgery: A Prospective Observational Study. Journal of Cardiothoracic and Vascular Anesthesia. 2016.
  50. 50. Al-Ghamdi A. Role of herpes simplex virus-1, cytomegalovirus and Epstein-Barr virus in atherosclerosis. Pakistan Journal of Pharmaceutical Sciences 2012. 25:89–97. pmid:22186314
  51. 51. Elkind M.S., Hills N.K., Glaser C.A., et al. Herpesvirus Infections and Childhood Arterial Ischemic Stroke: Results of the VIPS Study. Circulation 2016. 133:732–41. pmid:26813104
  52. 52. Elkind M.S., Ramakrishnan P., Moon Y.P., et al. Infectious burden and risk of stroke: the northern Manhattan study. Archives of Neurology 2010. 67:33–8. pmid:19901154
  53. 53. Kis Z., Sas K., Gyulai Z., et al. Chronic infections and genetic factors in the development of ischemic stroke. New Microbiol 2007. 30:213–20. pmid:17802898
  54. 54. Li M.L., Li Z.Z., Li S.P., He J.Y., and Wang Y.X. Stroke in progression, infection of herpes virus and neurologic impairment inhibited with antivirus druggery. Chinese Journal of Clinical Rehabilitation 2005. 9:158–161.
  55. 55. Ozturk A., Gunes M., Altinoz Aytar A., Ozturk C.E., and Ankarali H. Are some chronic infections probable risk factors for acute ischemic stroke? Turkiye Klinikleri Journal of Medical Sciences 2013. 33:726–731.
  56. 56. Ridker P.M., Hennekens C.H., Stampfer M.J., and Wang F. Prospective study of herpes simplex virus, cytomegalovirus, and the risk of future myocardial infarction and stroke. Circulation 1998. 98:2796–9. pmid:9860778
  57. 57. Sealy-Jefferson S., Gillespie B.W., Aiello A.E., Haan M.N., Morgenstern L.B., and Lisabeth L.D. Antibody Levels to Persistent Pathogens and Incident Stroke in Mexican Americans. PLoS ONE 2013. 8 (6) (no pagination).
  58. 58. Fullerton H.J., Luna J.M., Wintermark M., et al. Parvovirus B19 infection in children with arterial ischemic stroke. Stroke 2017. 48:2875–2877. pmid:28864597
  59. 59. Asiki G., Stockdale L., Kasamba I., et al. Pilot study of antibodies against varicella zoster virus and human immunodeficiency virus in relation to the risk of developing stroke, nested within a rural cohort in Uganda. Tropical Medicine & International Health 2015. 20:1306–10.
  60. 60. Askalan R., Laughlin S., Mayank S., et al. Chickenpox and stroke in childhood: a study of frequency and causation. Stroke 2001. 32:1257–62. pmid:11387484
  61. 61. Sebire G., Meyer L., and Chabrier S. Varicella as a risk factor for cerebral infarction in childhood: a case-control study. Annals of Neurology 1999. 45:679–80. pmid:10319896
  62. 62. Thomas S.L., Minassian C., Ganesan V., Langan S.M., and Smeeth L. Chickenpox and risk of stroke: a self-controlled case series analysis. Clinical Infectious Diseases 2014. 58:61–8. pmid:24092802
  63. 63. Kovac M., Lal H., Cunningham A.L., et al. Complications of herpes zoster in immunocompetent older adults: Incidence in vaccine and placebo groups in two large phase 3 trials. Vaccine 2018. 36:1537–1541. pmid:29463421
  64. 64. Baxter R., Tran T.N., Hansen J., et al. Safety of ZostavaxTM-A cohort study in a managed care organization. Vaccine 2012. 30:6636–6641. pmid:22963800
  65. 65. Tseng H.F., Liu A., Sy L., et al. Safety of zoster vaccine in adults from a large managed-care cohort: a Vaccine Safety Datalink study. Journal of Internal Medicine 2012. 271:510–20. pmid:22026504
  66. 66. Donahue J.G., Kieke B.A., Yih W.K., et al. Varicella vaccination and ischemic stroke in children: is there an association? Pediatrics 2009. 123:e228–34. pmid:19171574
  67. 67. MacDonald S.E., Dover D.C., Hill M.D., Kirton A., Simmonds K.A., and Svenson L.W. Is varicella vaccination associated with pediatric arterial ischemic stroke? A population-based cohort study. Vaccine 2018. 36:2764–2767. pmid:29655630
  68. 68. Xu J., Lupu F., and Esmon C.T. Inflammation, innate immunity and blood coagulation. Hamostaseologie 2010. 30:5–6, 8–9. pmid:20162248
  69. 69. Steiner I., Kennedy P.G., and Pachner A.R. The neurotropic herpes viruses: herpes simplex and varicella-zoster. Lancet Neurol 2007. 6:1015–28. pmid:17945155
  70. 70. Fugate J.E., Lyons J.L., Thakur K.T., Smith B.R., Hedley-Whyte E.T., and Mateen F.J. Infectious causes of stroke. The Lancet Infectious Diseases 2014. 14:869–880. pmid:24881525
  71. 71. Nagel M.A., Mahalingam R., Cohrs R.J., and Gilden D. Virus Vasculopathy and Stroke: An Under-Recognized Cause and Treatment Target. Infectious disorders drug targets 2010. 10:105–111. pmid:20166970
  72. 72. Morrison V.A., Johnson G.R., Schmader K.E., et al. Long-term persistence of zoster vaccine efficacy. Clin Infect Dis 2015. 60:900–9. pmid:25416754
  73. 73. Schmader K.E., Oxman M.N., Levin M.J., et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clin Infect Dis 2012. 55:1320–8. pmid:22828595
  74. 74. Feigin V.L., Krishnamurthi R.V., Parmar P., et al. Update on the Global Burden of Ischemic and Hemorrhagic Stroke in 1990–2013: The GBD 2013 Study. Neuroepidemiology 2015. 45:161–76. pmid:26505981
  75. 75. McKendrick M.W., McGill J.I., White J.E., and Wood M.J. Oral acyclovir in acute herpes zoster. Br Med J (Clin Res Ed) 1986. 293:1529–32.
  76. 76. Forbes H.J., Thomas S.L., Smeeth L., and Langan S.M. Prescription of antiviral therapy after herpes zoster in general practice: who receives therapy? Br J Gen Pract 2012. 62:e808–14. pmid:23211260